Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials

Édouard Auclin

doi:10.1016/j.ejca.2026.116955

Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials

2026-07-22

0

PRE

AI

É

Édouard Auclin

M

Matthieu Roulleaux-Dugage

T

Teresa Gorría

J

Juan Carlos Laguna

D

Diana Anguita

A

Angela Montes

M

M. Rota

M

Miquel Ferriol-Galmés

C

Charles Vauchier

P

Pernelle Lavaud

B

Benjamin Besse

L

L. Mezquita *

DOI：10.1016/j.ejca.2026.116955

Original

Original request for help

Save

Abstract

En 中文

• LIPI was evaluated in 1140 ES-SCLC patients from CASPIAN and IMpower133 trials. • Poor LIPI was associated with worse OS and PFS, regardless of treatment arm. • LIPI remained an independent prognostic factor in multivariate analyses. • Patients with good LIPI had longer survival with chemo-immunotherapy combinations. • LIPI may help identify ES-SCLC patients who benefit less from immunotherapy.

Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials

Abstract

Journal

Organization